GUILFORD, Conn. & NEW YORK–(BUSINESS WIRE) – Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), an innovative digital health company working to democratize medical imaging and improve global health equity, ushers in the next big change in veterinary medicine one of the new Butterfly iQ + Vet. The device of the second generation offers sharper imaging, a new tool for procedure management and hardware improvements that make the solution more powerful, more versatile and more user-friendly.
“Veterinarians provide incredible care and rise to the unique challenge of caring for patients who cannot speak,” said Todd Fruchterman, MD, PhD, president and chief executive officer of Butterfly. “They need clinical information that will help them make better decisions and efficiently achieve positive patient outcomes. This is where Butterfly iQ + Vet comes into play – we are creating a new shift in care that focuses on gaining important information from inside the body that our system can use in real time. ”
iQ + Vet has been carefully designed to provide high performance service to veterinarians in a wide variety of care settings.
Sharp pictures, quick answers
Over 800 hours of development work to optimize veterinary-specific clinical presets has resulted in vastly improved imaging in all applications. iQ + Vet comes with a number of powerful new features such as color Doppler sensitivity and increased maximum depth to help veterinarians collect the images they need for more informed care.
The innovative Needle Viz ™ tool is now available to veterinarians with five clinical presets (Bladder, MSK, MSK Equine, Small Organ and Vascular). The ability to visualize needles in the plane helps veterinarians perform fine needle aspirations more safely and, in emergency situations, quickly place lines and injections with greater confidence.
Hardware and software improvements now make it easier for veterinarians to take full advantage of iQ + Vet’s diagnostic capabilities. A 15% smaller probe area and a 10% shorter probe allow easier maneuvering for a large number of scans. Up to 20% longer battery life and an improved continuous running time before the thermal shutdown ensure that iQ + Vet works even longer in the clinic or in the field. Butterfly’s veterinary software now includes customizable worksheets to help users capture the precise information needed for each individual patient.
Compatibility and price flexibility
Now with Android compatibility and the option for a USB-C or Lightning cable, iQ + Vet is introducing a whole new group of veterinarians and practices to the diagnostic power of portable ultrasound. Additionally, Butterfly has introduced flexible pricing options to meet the needs of veterinary customers in a variety of care settings, including rental and direct purchase options.
Global expansion and partnerships
With the new value the device offers and the growing global demand, Butterfly has iQ + Vet now available for purchase in 19 new international markets: Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands , New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland and the United Kingdom.
The international expansion has made exciting new partnerships possible. Butterfly expands its collaboration with MWI Animal Health, a leading distributor of animal health products and services. MWI UK will support the distribution of Butterfly iQ + Vet to veterinary practices in the UK. Butterfly is also entering into a new partnership in Australia and New Zealand with REM SYSTEMS, part of Paragon Care Group, an established veterinary retailer. These are important first steps in the growth of Butterfly’s veterinary presence outside of the United States.
In the United States, Butterfly is increasing its impact by announcing a large-scale innovation partnership with Rarebreed Veterinary Partners, a strategic partner that is growing and supporting veterinary clinics in the eastern United States. Rarebreed will use iQ + Vet system-wide in its innovative community of veterinary practices.
“Rarebreed is excited to partner with Butterfly to bring ultrasound to more patients,” said Dan Espinal, co-founder and CEO of Rarebreed. “Rarebreed exists to improve the standard of care throughout the profession and to bring innovations to our partner practices. Ultrasound should be an integral part of almost every diagnostic workup. ”
“Our partnership with Rarebreed to roll out iQ + Vet system-wide is a great example of recognizing the potential and impact of iQ + Vet for leading veterinary practices to improve their care,” said Darius Shahida, Butterfly Network’s Chief Strategy & Business Development Officer . “Not only will Rarebreed vets incorporate this powerful diagnostic tool into their practices to provide new and faster insights, but this deployment will further strengthen the bond these vets have with their pet owners seeking the best care for their pets.”
By building such partnerships and increasing access to this diagnostic solution, Butterfly has the potential to transform veterinary medicine. The powerful, cross-species, and easy-to-use imaging solution will help veterinarians around the world utilize diagnostic capabilities and ensure more effective care.
Butterfly will host a virtual kick-off event on October 5, 2021 at 5 p.m. EDT to share more details. Reserve your seat today on Butterfly’s veterinary website. Butterfly iQ + Vet will be available for sale online until the end of the day in the regions where the product is commercially available.
Via the butterfly network
Butterfly Network was founded in 2011 by Dr. Jonathan Rothberg and was recently listed on the NYSE through a merger with Longview Acquisition Corp (NYSE: BFLY). Butterfly iQ + Vet. Butterfly’s mission is to provide universal access to superior medical imaging, and part of that mission is to scan every animal on every vet visit. With its proprietary Ultrasound-on-ChipTM technology, Butterfly paves the way for earlier detection and remote management of health conditions around the world. The Butterfly iQ + Vet can be purchased online in-store by veterinarians in approved countries or by contacting sales at firstname.lastname@example.org.
Rarebreed Veterinary Partners is a thriving community of veterinary clinics committed to creating exceptional work experiences, one partnership or one team member at a time. We pride ourselves on building trusting, lasting relationships with our partner hospitals with the goal of delivering exceptional patient care, outstanding customer service and an amazing work experience. We continue to build a wide network of practices that health teams value by providing them with the innovations and tools needed to grow, improve, and reshape the veterinary experience. More information is available at www.rarebreedvet.com.
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Actual results could differ from its expectations, estimates and projections and therefore you should not rely on them Forward-looking statements are relied on as predictions of future events. Words like “expect”, “estimate”, “plan”, “budget”, “forecast”, “foresee”, “intend”, “plan”, “can”, “will”, “could”, “should” ” believes, “” forecasts, “” potentially, “continues,” and similar expressions (or the negative versions of such words or phrases) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the company’s expectations regarding future performance and development of products and services. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are beyond the control of the company and difficult to predict. Factors that can cause such differences include, but are not limited to: the impact of COVID-19 on the company’s business; the ability to see the anticipated benefits of the business combination; the company’s ability to grow and to manage growth profitably; the success, cost, and timing of the company’s product and service development activities; the potential features and benefits of the company’s products and services; the company’s ability to obtain and maintain regulatory approval for its products and any associated restrictions and restrictions on an approved product; the company’s ability to identify, license, or acquire additional technology; the company’s ability to maintain its existing license, manufacturing, supply and distribution agreements; the company’s ability to compete with other companies that are currently marketing or developing products and services that the company is currently marketing or developing; Changes in applicable laws or regulations; the size and potential for growth of the markets for the company’s products and services and its ability to serve those markets alone or in partnership with others; the pricing of the Company’s products and services and the reimbursement of medical procedures performed with its products and services; the company’s estimates of expenses, income, capital requirements, and additional funding requirements; the company’s financial performance; the company’s ability to raise funding in the future; and other risks and uncertainties disclosed from time to time in the company’s filings with the Securities and Exchange Commission. The company advises that the above list of factors is not exclusive. The company cautions you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The company undertakes no obligation, or undertakes, to publicly release any updates or revisions to any forward-looking statement to reflect changes in company expectations or changes in the events, conditions or circumstances on which any such statement is based.